Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Published online before print December 18, 2008, 10.1148/radiol.2501080291

(Radiology 2009;250:407.)

A more recent version of this article appeared on February 1, 2009
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow All Versions of this Article:
2501080291v1
250/2/407    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by d'Assignies, G.
Right arrow Articles by Vilgrain, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by d'Assignies, G.
Right arrow Articles by Vilgrain, V.
© RSNA, 2008

Gastrointestinal Imaging

Pancreatic Endocrine Tumors: Tumor Blood Flow Assessed with Perfusion CT Reflects Angiogenesis and Correlates with Prognostic Factors1

Gaspard d'Assignies, MD, Anne Couvelard, MD, Stéphane Bahrami, MD, Marie-Pierre Vullierme, MD, Pascal Hammel, MD, Olivia Hentic, MD, Alain Sauvanet, MD, Pierre Bedossa, MD, Philippe Ruszniewski, MD, and Valérie Vilgrain, MD

1 From the Departments of Radiology (G.d.A., M.P.V., V.V.) and Pathology (A.C., P.B.), INSERM Unité 773 CRB3 (A.C., P.B., V.V.), and the Fédération Médico Chirurgicale (P.H., O.H., A.S., P.R.), Beaujon Hospital, 100 boulevard général Leclerc, 92110 Clichy La Garenne, France; and Department of Epidemiology, Biostatistics and Clinical Research, Hôpital Bichat, APHP, University of Paris 7, Paris, France (S.B.). Received February 12, 2008; revision requested May 1; revision received June 17; accepted July 3; final version accepted July 22. Supported by a grant from the Roche Foundation. Address correspondence to G.d.A. (e-mail: gdassignies{at}gmail.com).

Purpose: To prospectively correlate multidetector computed tomographic (CT) perfusion measurement of pancreatic endocrine tumors with tumor microvascular density (MVD) assessed by using histologic techniques and to determine whether perfusion CT parameters differ between tumor grades.

Materials and Methods: Institutional review board approval and informed consent were obtained. Thirty-six patients (15 men, 21 women; mean age, 53 years; range, 18–78 years) with resectable pancreatic endocrine tumors underwent presurgical dynamic perfusion CT. Twenty-eight (78%) of 36 patients were included in the study group; eight were excluded because of artifacts that were not compatible with perfusion postprocessing. Multidetector CT perfusion data were analyzed to calculate tumor and normal pancreatic blood flow, blood volume, mean transit time, and permeability–surface area product. Multidetector CT perfusion parameters were compared with intratumoral MVD by using the Spearman correlation coefficient and with World Health Organization (WHO) classification, tumor size, tumor proliferation index, hormonal profile, and presence of metastases by using Mann-Whitney tests.

Results: High correlation (r = 0.620, P < .001) was observed between tumor blood flow and intratumoral MVD. Blood flow was significantly higher (P = .02) in the group of benign tumors (WHO 1) than in the groups of tumors of indeterminate prognosis (WHO 2) or well-differentiated carcinomas (WHO 3). Blood flow was significantly higher in tumors with a proliferation index of 2% or less (P = .005) and in those without histologic signs of microscopic vascular involvement (P = .008). Mean transit time was longer in tumors with lymph node (P = .02) or liver (P = .05) metastasis.

Conclusion: Perfusion CT is feasible in patients with pancreatic endocrine tumors and reflects MVD. Perfusion CT measurements are correlated with histoprognostic factors, such as proliferation index and WHO classification.

© RSNA, 2008